Therapy of Exacerbation of Chronic Bronchitis in Ambulatory Practice: the Results of the Pharmacoepidemiological Study | CMAC

Therapy of Exacerbation of Chronic Bronchitis in Ambulatory Practice: the Results of the Pharmacoepidemiological Study

Clinical Microbiology and Antimicrobial Chemotherapy. 2001; 3(2):148-155

​ Kozlov S.N., Rachina S.A., Domnikova N.P., Karpov O.I., Kuzin V.B., Leshchenko I.V., Likhatchova R.J., Nedogoda S.V., Stratchounski L.S.
exacerbation of chronic bronchitis antimicrobial therapy pharmacoepidemiology
Section
Antimicrobial Use
Type
Journal article
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2001; 3(2):148-155

Abstract

Case histories of outpatients with acute exacerbation of chronic bronchitis (AECB) were analyzed. Diagnoses were classified according to the ICD-10, antimicrobials – to the ATC classification. Altogether 783 case histories of patients aged from 16 to 92 (average age 51,6+13,7) were included in the study. The most frequently prescribed group of medications were antimicrobials for systemic use (83,9%), cough and cold preparations (75,5%), bronchodilators (48,7%), antihistamines (23,0%) and vitamins (9,7%). The most common antimicrobial prescribed was co-trimoxazole (31,8%), followed by ciprofloxacin (16,4%), ampicillin (14,5%) and gentamуcin (10,0%). For antimicrobial treatment monotherapy was used in 84,8% of cases, combination of 2–3 antibiotics – in 15,2% of patients. Average duration of antimicrobial therapy was 8,2+3,4 days. The most common bronchodilators prescribed were preparations of theophylline (76,1%), M-anticholinergic agents (15,4%) and complex ephedrine-containing medications (14,9%). This study has shown unacceptably high rate of inappropriate approach to the therapy of AECB: irrational choice of antibacterials, use of archaic and potentially toxic drugs, wide use of medications with non-proven clinical efficacy.

  • 1. Reynolds H.Y. Chronic bronchitis and acute infectious exacerbations. Principles and Practice of Infectious Diseases. 5th ed. Philadelphia: Churchill Livingstone; 2000. p. 706-10.
  • 2. Ball P., Make B. Acute exacerbations of chronic bronchitis. An international comparison. Chest 1998; 113: 199-204.
  • 3. Ball P. Epidemiology and treatment of chronic bronchitis and its exacerbations. Chest 1995; 108 (Suppl): 43-52.
  • 4. Niederman M.S. The role of quinolones in the treatment of acute exacerbations of chronic bronchitis. Infect Med 1999; 16: 5-7.
  • 5. Madison J.M. Chronic obstructive pulmonary disease. Lancet 1998; 352: 467-73.
  • 6. Seemungal T.A., Harper-Owen R., Bhowmik A., Sapsford R., Jefferies D.J., Wedzicha J.A. Rhinovirus infects the lower respiratory tract during COPD exacerbation. Thorax 1999; 54(Suppl 3):Abstract.A70.
  • 7. Donaldson G.S., Seemungal T.A., Jefferies D.J., Wedzicha J.A. Effect of temperature on lung function and symptoms in chronic obstructive pulmonary disease. Eur Respir J 1999; 13: 844-9.
  • 8. Niederman M.S. COPD: the role of infection. Chest 1997; 112: 301-2.
  • 9. Anzueto A., Niederman M.S. Tillotson G.S. Etiology, susceptibility, and treatment of acute bacterial exacerbations of complicated chronic bronchitis in the primary care setting: ciprofloxacin 750 mg b.i.d. versus clarithromycin 500 mg b.i.d. Bronchitis Study Group. Clin Ther 1998; 20: 885-900.
  • 10. Anthonisen N.R., Manfreda J., Warren C.P.W., Hershfield E.S., Harding G.K.M., Nelson N.A. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106:196-204.
  • 11. Monso E., Ruiz J., Rosell A., Manterola J., Fiz J., Morera J., Ausina V. Bacterial infection in chronic obstructive pulmonary disease. A study of stable and exacerbated outpatients using the protected specimen brush. Am J Respir Crit Care Med 1995; 152: 1316-20.
  • 12. Saint S., Bent S., Vittinghoff E. Grady D. Antibiotics in chronic obstructive pulmonary disease exacerbations: a meta-analysis. JAMA 1995; 273: 957-60.
  • 13. Anzueto A., Rizzo J.A., Grossman R.F. The infection-free interval: its use in evaluating antimicrobial treatment of acute exacerbation of chronic bronchitis. Clin Infect Dis 1999; 28: 1344-5.
  • 14. Grossman R., Mukherjee J., Vaughan D., Eastwood C., Cook R., Laforge J., et al. A 1-year community-based health economic study of ciprofloxacin vs usual antibiotic treatment in acute exacerbations of chronic bronchitis: the Canadian Ciprofloxacin Health Economic Study Group. Chest 1998; 113: 131-41.
  • 15. Ball P., Harris J.M., Lowson D., Tillotson G., Wilson R. Acute infective exacerbations of chronic bronchitis. Q J Med 1995; 88: 61-8.
  • 16. Страчунский Л.С., Богданович Т.М. Состояние антибиотикорезистентности в России. В кн.: Антибактериальная терапия. Практическое руководство. Под ред. Страчунского Л.С., Белоусова Ю.Б., Козлова С.Н. Москва: РЦ "Фармединфо"; 2000. с."7-11.
  • 17. Miravitlles M., Espinosa C., Fernandez-Laso E., Martos J.A., Maldonado J.A., Gallego M. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Chest 1999; 116: 40-6.
  • 18. Страчунский Л.С., Козлов С.Н. Макролиды в современной клинической практике. Смоленск: Русич; 1998.
  • 19. Mandell G.L., Perti W.A. Jr. Penicillins, Cephalosporins, and other b-lactam antibiotics. In: Hardman J.G., Limbird L.E., Molinoff P.B., Ruddon R.W., editors. The Pharmacological Basis of Therapeutics. 9th ed. New York: McGraw-Hill; 1996. p. 1073-102.
  • 20. Gilbert D.N. Aminoglycosides. In: Mandell G.L., Bennett J.E., Dolin R., editors. Principles and Practice of Infectious Diseases. 5th ed. Philadelphia: Churchill Livingstone; 2000. p. 307-36.
  • 21. Serafin W.E. Drugs used in the treatment of asthma. In: Hardman J.G., Limbird L.E., Molinoff P.B., Ruddon R.W., editors. The Pharmacological Basis of Therapeutics. 9th ed. New York: McGraw-Hill; 1996. p. 659-82.
  • 22. Poole P.J., Black P.N. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. In: Cochrane Collaboration. Cochrane Library. Issue 5. Oxford: Update Software; 2000.
  • 23. Lester L.A. Mucolytic Therapies. In: Leff A.R., editor. Pulmonary and Critical Care Pharmacology and Therapeutics. 1st ed. New York: McGraw-Hill; 1996. p. 681-94.
  • 24. Hoffman B.B., Lefkowitz R.J. Catecholamines, sympathomimetic drugs, and adrenergic receptor antagonists. Drugs used in the treatment of asthma. In: Hardman J.G., Limbird L.E., Molinoff P.B., Ruddon R.W., editors. The Pharmacological Basis of Therapeutics. 9th ed. New York: McGraw-Hill; 1996. p. 199-248.
  • 25. Rauwels R.A., Lofdahl C-G., Laitinen L.A., Schouten J.P., Postma D.S., Pride N.B., et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N Engl J Med 1999; 340: 1948-53.
  • 26. Burge P.S., Calverley P.M.A., Jones P.W., Spenser S., Anderson J.A., Maslen T.K. Randomised, double-blind, placebo-controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320: 1297-303.
  • 27. Niewoehner D.E., Erbland M.L., Deupree R.H., Collins D., Gross N.J., Light R.W., et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. N Engl J Med 1999; 340: 1941-7.
  • 28. Barnes P.J. Chronic obstructive pulmonary disease. N Engl J Med 2000; 343: 269-80.
Views
0 Abstract
0 PDF
0 Crossref citations
Shared